Nectar Lifesciences Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹24.96
- Today's High:
- ₹26.65
- Open Price:
- ₹26.42
- 52W Low:
- ₹14.36
- 52W High:
- ₹30.55
- Prev. Close:
- ₹26.36
- Volume:
- 72671
Company Statistics
- Market Cap.:
- ₹6.24 billion
- Book Value:
- 47.471
- Revenue TTM:
- ₹15.15 billion
- Operating Margin TTM:
- -0.8%
- Gross Profit TTM:
- ₹3.64 billion
- Profit Margin:
- -1.73%
- Return on Assets TTM:
- -0.14%
- Return on Equity TTM:
- -2.25%
Company Profile
Nectar Lifesciences Limited had its IPO on under the ticker symbol NECLIFE.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Nectar Lifesciences Limited has a staff strength of 1,589 employees.
Stock update
Shares of Nectar Lifesciences Limited opened at ₹26.42 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹24.96 - ₹26.65, and closed at ₹25.09.
This is a -4.82% slip from the previous day's closing price.
A total volume of 72,671 shares were traded at the close of the day’s session.
In the last one week, shares of Nectar Lifesciences Limited have slipped by -6.69%.
Nectar Lifesciences Limited's Key Ratios
Nectar Lifesciences Limited has a market cap of ₹6.24 billion, indicating a price to book ratio of 0.4823 and a price to sales ratio of 0.2983.
In the last 12-months Nectar Lifesciences Limited’s revenue was ₹15.15 billion with a gross profit of ₹3.64 billion and an EBITDA of ₹475.78 million. The EBITDA ratio measures Nectar Lifesciences Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Nectar Lifesciences Limited’s operating margin was -0.8% while its return on assets stood at -0.14% with a return of equity of -2.25%.
In Q2, Nectar Lifesciences Limited’s quarterly earnings growth was a negative -52.9% while revenue growth was a negative 2.2%.
Nectar Lifesciences Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at ₹-1.12 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nectar Lifesciences Limited’s profitability.
Nectar Lifesciences Limited stock is trading at a EV to sales ratio of 0.6568 and a EV to EBITDA ratio of 8.4231. Its price to sales ratio in the trailing 12-months stood at 0.2983.
Nectar Lifesciences Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹21.89 billion
- Total Liabilities
- ₹8.91 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Nectar Lifesciences Limited ended 2024 with ₹21.89 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹21.89 billion while shareholder equity stood at ₹10.65 billion.
Nectar Lifesciences Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹8.91 billion in other current liabilities, in common stock, ₹6.95 billion in retained earnings and ₹0.00 in goodwill. Its cash balance stood at ₹175.80 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹2.26 billion.
Nectar Lifesciences Limited’s total current assets stands at ₹12.31 billion while long-term investments were ₹0 and short-term investments were ₹420.73 million. Its net receivables were ₹2.80 billion compared to accounts payable of ₹3.19 billion and inventory worth ₹6.73 billion.
In 2024, Nectar Lifesciences Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Nectar Lifesciences Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹25.09
- 52-Week High
- ₹30.55
- 52-Week Low
- ₹14.36
- Analyst Target Price
- ₹
Nectar Lifesciences Limited stock is currently trading at ₹25.09 per share. It touched a 52-week high of ₹30.55 and a 52-week low of ₹30.55. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹24.37 and 200-day moving average was ₹20.54 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5704.1% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Nectar Lifesciences Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company’s active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company provides menthol and mint derivatives and empty hard gelatin capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.